Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses

February 15, 2026 updated by: Diana SAS

Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses: A Double-blind, Randomised, Placebo-controlled Study.

The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The main objective of this study is to assess efficacy of the product on skin translucency after 84 days of product compared to a placebo. The study will also evaluate the effect of the product on different skin parameters (radiance, firmness, elasticity, skin barrier function, skin pH, blood flow) with different instruments. The quality of life and the improvement of skin properties will also be collected with questionnaires completed by the subjects. Finally, the safety of this product will be assessed by collecting all adverse events that might occur during the study.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
108

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: Lionel NOAH (Senior Scientific Manager), Ph. D.
  • Phone Number: +33 7 87 32 06 03
  • Email: lionel.noah@symrise.com

Study Locations

  • China
      • Guangzhou, China
        • EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Healthy women.
  2. Chinese.

  3. Age: in each group of products

    • 50% of subject having 30 to 45 years old
    • 50% of subject having 46 to 60 years old
  4. Phototype: II to IV.
  5. Subject with dull skin from grade 3 to 7 on skin dullness 9 points scale.
  6. Subject exposed to high air pollution up to 2 to 3 hours per day (traffic roads, cigarette smoke, dusts or small particles).
  7. Subject who accepts daily exposition to blue light (mobile phone, Ipad, laptop or get exposure to LED light) at home (at least 2h).
  8. Subject with at least 1 spot on the face.
  9. Subject with BMI ≤ 30
  10. Subject, psychologically able to understand the study related information and to give a written informed consent.
  11. Subject having given freely and expressly her informed consent.
  12. Subject agreeing to not change her alimentary and cosmetic habits on the studied area during the study.

Exclusion Criteria:

In term of population :

  1. Pregnant or nursing woman or planning a pregnancy during the study.
  2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
  3. Minor subject.
  4. Major subject who is under guardianship or who is not able to express her consent.
  5. Subject in a social or sanitary establishment.

  6. Subject suspected to be non-compliant according to the investigator's judgment.

    In term of associated pathology :

  7. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
  8. Subject suffering from a severe or progressive disease.
  9. Subject with known history of or suffering from skin disease that may interfere with evaluation of the study results and/or subject safety.

  10. Subject having history of severe allergy or anaphylactic shock including known risk of hypersensitivity to one of the components of the composition of the product

    Related to previous or ongoing treatment :

  11. Subject undergoing a topical treatment on the test area or a systemic treatment:

    • anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
    • corticosteroids during the 2 previous weeks and during the study;
    • retinoids and/or immunosuppressors during the 3 previous months and during the study;
    • any medication stabilized for less than one month.
  12. Subject having started or changed her oral contraceptive or any other hormonal treatment during the three previous months.
  13. Subject having done facial skin care like peeling, mask… during the previous 2 weeks and during the study.

  14. Subject having used oral nutritional supplements and/or vitamin supplementation during the previous month and during the study

    In term of lifestyle :

  15. Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
  16. Subject having used topical products containing actives substances during the previous 2 weeks and during the study
  17. Subject planning to change her life habits during the study.
  18. Subject with unstable eating habits or planning to change them during the study
  19. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 5 cigarettes per day).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Other: Placebo
4 capsules per day, each capsule containing 400 mg of maltodextrin
Experimental: Acerola Juice Powder 1200 mg/day
Higher dose
Dietary supplement: Acerola Juice Powder 1200 mg/day
4 capsules per day, each capsule containing 300mg of Acerola and 100 mg of maltodextrin
Experimental: Acerola Juice Powder 600 mg/day
Lower dose
Dietary supplement: Acerola Juice Powder 600 mg/day
4 capsules/day, each capsule containing 150 mg of Acerola and 250 mg of Maltodextrin

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change from baseline on skin translucency parameter Alpha at 84 days
Time Frame: From enrollment to 84 days of supplementation
The skin translucency parameter Alpha is measured with translucency meter
From enrollment to 84 days of supplementation

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change from baseline on skin translucency parameters Alpha, Area and K at 28 days and 84 days
Time Frame: From enrollment to 28 days of supplementation
The skin translucency parameters Alpha, Area and Kis are measured with translucency meter
From enrollment to 28 days of supplementation
Change from baseline on skin complexion radiance at 14, 28, 56 and 84 days
Time Frame: From enrollment to 14, 28, 56 and 84 days of supplementation
Skin complexion radiance measured with Colorface®
From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on pigment spot at 14, 28, 56 and 84 days
Time Frame: From enrollment to 14, 28, 56 and 84 days of supplementation
Pigment spot measured with Colorface®
From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on skin firmness, elasticity and fatigability at 28 and 84 days
Time Frame: From enrollment to 28 and 84 days of supplementation
Skin firmness, elasticity and fatigability measured with Cutometer®
From enrollment to 28 and 84 days of supplementation
Change from baseline on Trans Epidermal Water Loss at 28 and 84 days
Time Frame: From enrollment to 28 and 84 days of supplementation
Trans Epidermal Water Loss measured with Tewameter®
From enrollment to 28 and 84 days of supplementation
Product safety
Time Frame: From enrolment to 84 days
Safety assessed by the collection of adverse events and concomitant treatments throughout the study
From enrolment to 84 days

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change from baseline on skin pH at 28 and 84 days
Time Frame: From enrollment to 28 and 84 days of supplementation
Skin pH measured with pH meter
From enrollment to 28 and 84 days of supplementation
Change from baseline on blood flow at 28 and 84 days
Time Frame: From enrollment to 28 and 84 days of supplementation
Blood flow measured with Laser speckle blood flow imager®
From enrollment to 28 and 84 days of supplementation
Change from baseline on subject quality of life at 28 and 84 days
Time Frame: From enrollment to 28 and 84 days of supplementation
Quality of life assessed using the questionnaire SF-12 completed by the subjects
From enrollment to 28 and 84 days of supplementation
Change from baseline on subject satisfaction at 28 and 84 days
Time Frame: From enrollment to 28 and 84 days of supplementation
Subject satisfaction assessed with a subjective evaluation questionnaire developed by the Sponsor completed by the subjects
From enrollment to 28 and 84 days of supplementation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Diana SAS

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Eurofins Dermscan Pharmascan

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Sarah ZENG, EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 3, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 13, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 13, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 13, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 13, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 14, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 18, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 15, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GZ25205020P

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings